NCT04566770View on ClinicalTrials.gov

A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

PHASE2CompletedINTERVENTIONAL
Enrollment

480

Participants

Timeline

Start Date

September 24, 2020

Primary Completion Date

September 21, 2021

Study Completion Date

January 19, 2022

Conditions
COVID-19
Interventions
BIOLOGICAL

Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

Intramuscular other name:Ad5-nCoV

BIOLOGICAL

Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo

Intramuscular other name:Ad5-nCoV

Trial Locations (1)

210000

Taixing City center for Disease Control and Prevention, Taizhou

Sponsors
All Listed Sponsors
collaborator

Beijing Institute of Biotechnology

OTHER

collaborator

Jiangsu Province Centers for Disease Control and Prevention

NETWORK

lead

CanSino Biologics Inc.

INDUSTRY

NCT04566770 - A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) | Biotech Hunter | Biotech Hunter